+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Top 10 Cancer Drugs Market by Region: Opportunity Analysis and Industry Forecast, 2018-2026

  • ID: 4989490
  • Report
  • November 2019
  • Region: Global
  • 189 pages
  • Allied Analytics LLP
1 of 5

Enquire about COVID-19 updates for this product.

Enquire Now

FEATURED COMPANIES

  • AbbVie Inc.
  • Astellas Pharma Inc.
  • AstraZeneca PLC
  • Celgene Corporation
  • F. Hoffmann-La Roche Ltd.
  • Merck & Co. Inc.
  • MORE
The global top 10 cancer drugs sales was valued at $63,619 million in 2018 and is expected to reach $129,948 million by 2026, registering a CAGR of 9.8% from 2019 to 2026.
Cancer is a medical condition in which abnormal cells grow with the potential to invade or spread to other parts of the body. Different forms of the drugs used for the treatment of cancer majorly include, chemotherapy, targeted therapy, immunotherapy, and others.

Increase in prevalence of various forms of cancer, increase in popularity of advance therapies such as biological & targeted drug therapies, and rise in geriatric population worldwide are the key factors that drive the growth of the global cancer drugs market. Furthermore, rise in cancer awareness, increase in R&D activities, and availability of cancer drugs are expected to boost the market growth.

However, the high cost involved in new drug development coupled with threat of failure and adverse effects associated with cancer drugs therapies is expected to restrain the growth of the market. Conversely, high potential of emerging economies and increase in number of pipeline products are expected to provide new opportunities for market players in future.

The global top 10 cancer drugs market is segmented on the basis of region into Europe (Russia, Netherlands, Switzerland, Sweden, Belgium, Austria, Norway, Denmark, Poland, Finland, Portugal, Greece, Ireland, Czech Republic, Hungary, Romania, Ukraine), Asia-Pacific (Taiwan, Indonesia, New Zealand, Singapore, Malaysia, Vietnam, Myanmar, Sri Lanka, Macau, Nepal), and LAMEA (Turkey, Venezuela, Colombia, Argentina, Iran, Israel, Chile, Algeria, UAE, Puerto Rico, Morocco, Costa Rica, Lebanon).

KEY BENEFITS FOR STAKEHOLDERS
  • This report entails a detailed quantitative analysis along with the current global Top 10 cancer drugs market trends from 2019 to 2026 to identify the prevailing opportunities along with the strategic assessment.
  • The market size and estimations are based on a comprehensive analysis of key developments in the industry.
  • A qualitative analysis based on innovative products facilitates strategic business planning.
  • The development strategies adopted by the key market players are enlisted to understand the competitive scenario of the market
Key Market Segments

By Region
  • Europe
  • Russia
  • Netherlands
  • Switzerland
  • Sweden
  • Belgium
  • Austria
  • Norway
  • Denmark
  • Poland
  • Finland
  • Portugal
  • Greece
  • Ireland
  • Czech Republic
  • Hungary
  • Romania
  • Ukraine
  • LAMEA
  • Turkey
  • Venezuela
  • Colombia
  • Argentina
  • Iran
  • Israel
  • Chile
  • Algeria
  • United Arab Emirates
  • Puerto Rico
  • Morocco
  • Costa Rica
  • Lebanon
List of key players profiled in the report:
  • AbbVie Inc.
  • Astellas Pharma Inc.
  • AstraZeneca PLC
  • Bristol-Myers Squibb Company
  • Celgene Corporation
  • F. Hoffmann-La Roche Ltd.
  • Johnson & Johnson (Janssen Global Services, LLC,)
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
LIST OF OTHER PLAYERS IN THE VALUE CHAIN (These players are not profiled in the report. The same will be included on request)
  • Sanofi S.A.
  • Amgen Inc.
  • Bayer AG
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • AbbVie Inc.
  • Astellas Pharma Inc.
  • AstraZeneca PLC
  • Celgene Corporation
  • F. Hoffmann-La Roche Ltd.
  • Merck & Co. Inc.
  • MORE
Chapter 1: Introduction
1.1. Report Description
1.2. Key Benefits For Stakeholders
1.3. Key Market Segments
1.4. Research Methodology
1.4.1. Secondary Research
1.4.2. Primary Research
1.4.3. Analyst Tools And Models

Chapter 2: Executive Summary
2.1. Key Findings Of The Study
2.2. CXO Perspective

Chapter 3: Market Overview
3.1. Market Definition And Scope
3.2. Key Findings
3.2.1. Top Investment Pockets
3.3. Top Player Positioning, 2018
3.4. Porter’s Five Forces Analysis
3.5. Market Dynamics
3.5.1. Drivers
3.5.1.1. Rise In Incidence Of Cancer Across The Globe
3.5.1.2. Surge In Global Geriatric Population
3.5.1.3. Increase In Government Expenditure On Healthcare
3.5.2. Restraints
3.5.2.1. Adverse Effects Associated With The Use Cancer Drugs
3.5.3. Opportunities
3.5.3.1. High Growth Potential In Untapped Emerging Economies
3.5.3.2. Increase In Number Of Pipeline Drugs
3.5.4. Impact Analysis

Chapter 4: Cancer Drugs Market, By Region
4.1. Overview
4.1.1. Global Sales Of Top 50 Anticancer Drugs
4.2. Europe
4.2.1. Key Market Trends, Growth Factors, And Opportunities
4.2.2. Market Size And Forecast, By Country
4.2.2.1. Russia Cancer Drugs Market
4.2.2.1.1. Russia Sales Of Top 10 Cancer Drugs
4.2.2.2. Netherlands Cancer Drugs Market
4.2.2.2.1. Netherlands Sales Of Top 10 Cancer Drugs
4.2.2.3. Switzerland Cancer Drugs Market
4.2.2.3.1. Switzerland Sales Of Top 10 Cancer Drugs
4.2.2.4. Sweden Cancer Drugs Market
4.2.2.4.1. Sweden Sales Of Top 10 Cancer Drugs
4.2.2.5. Belgium Cancer Drugs Market
4.2.2.5.1. Belgium Sales Of Top 10 Cancer Drugs
4.2.2.6. Austria Cancer Drugs Market
4.2.2.6.1. Austria Sales Of Top 10 Cancer Drugs
4.2.2.7. Norway Cancer Drugs Market
4.2.2.7.1. Norway Sales Of Top 10 Cancer Drugs
4.2.2.8. Denmark Cancer Drugs Market
4.2.2.8.1. Denmark Sales Of Top 10 Cancer Drugs
4.2.2.9. Poland Cancer Drugs Market
4.2.2.9.1. Poland Sales Of Top 10 Cancer Drugs
4.2.2.10. Finland Cancer Drugs Market
4.2.2.10.1. Finland Sales Of Top 10 Cancer Drugs
4.2.2.11. Portugal Cancer Drugs Market
4.2.2.11.1. Portugal Sales Of Top 10 Cancer Drugs
4.2.2.12. Greece Cancer Drugs Market
4.2.2.12.1. Greece Sales Of Top 10 Cancer Drugs
4.2.2.13. Ireland Cancer Drugs Market
4.2.2.13.1. Ireland Sales Of Top 10 Cancer Drugs
4.2.2.14. Czech Republic Cancer Drugs Market
4.2.2.14.1. Czech Republic Sales Of Top 10 Cancer Drugs
4.2.2.15. Hungary Cancer Drugs Market
4.2.2.15.1. Hungary Sales Of Top 10 Cancer Drugs
4.2.2.16. Romania Cancer Drugs Market
4.2.2.16.1. Romania Sales Of Top 10 Cancer Drugs
4.2.2.17. UKraine Cancer Drugs Market
4.2.2.17.1. UKraine Sales Of Top 10 Cancer Drugs
4.3. Asia-Pacific
4.3.1. Key Market Trends, Growth Factors, And Opportunities
4.3.2. Market Size And Forecast, By Country
4.3.2.1. Taiwan Cancer Drugs Market
4.3.2.1.1. Taiwan Sales Of Top 10 Cancer Drugs
4.3.2.2. Indonesia Cancer Drugs Market
4.3.2.2.1. Indonesia Sales Of Top 10 Cancer Drugs
4.3.2.3. New Zealand Cancer Drugs Market
4.3.2.3.1. New Zealand Sales Of Top 10 Cancer Drugs
4.3.2.4. Singapore Cancer Drugs Market
4.3.2.4.1. Singapore Sales Of Top 10 Cancer Drugs
4.3.2.5. Malaysia Cancer Drugs Market
4.3.2.5.1. Malaysia Sales Of Top 10 Cancer Drugs
4.3.2.6. Vietnam Cancer Drugs Market
4.3.2.6.1. Vietnam Sales Of Top 10 Cancer Drugs
4.3.2.7. Myanmar Cancer Drugs Market
4.3.2.7.1. Myanmar Sales Of Top 10 Cancer Drugs
4.3.2.8. Sri Lanka Cancer Drugs Market
4.3.2.8.1. Sri Lanka Sales Of Top 10 Cancer Drugs
4.3.2.9. Macau Cancer Drugs Market
4.3.2.9.1. Macau Sales Of Top 10 Cancer Drugs
4.3.2.10. Nepal Cancer Drugs Market
4.3.2.10.1. Nepal Sales Of Top 10 Cancer Drugs
4.4. LAMEA
4.4.1. Key Market Trends, Growth Factors, And Opportunities
4.4.2. Market Size And Forecast, By Country
4.4.2.1. Turkey Cancer Drugs Market
4.4.2.1.1. Turkey Sales Of Top 10 Cancer Drugs
4.4.2.2. Venezuela Cancer Drugs Market
4.4.2.2.1. Venezuela Sales Of Top 10 Cancer Drugs
4.4.2.3. Colombia Cancer Drugs Market
4.4.2.3.1. Colombia Sales Of Top 10 Cancer Drugs
4.4.2.4. Argentina Cancer Drugs Market
4.4.2.4.1. Argentina Sales Of Top 10 Cancer Drugs
4.4.2.5. Iran Cancer Drugs Market
4.4.2.5.1. Iran Sales Of Top 10 Cancer Drugs
4.4.2.6. Israel Cancer Drugs Market
4.4.2.6.1. Israel Sales Of Top 10 Cancer Drugs
4.4.2.7. Chile Cancer Drugs Market
4.4.2.7.1. Chile Sales Of Top 10 Cancer Drugs
4.4.2.8. Algeria Cancer Drugs Market
4.4.2.8.1. Algeria Sales Of Top 10 Cancer Drugs
4.4.2.9. Uae Cancer Drugs Market
4.4.2.9.1. Uae Sales Of Top 10 Cancer Drugs
4.4.2.10. Puerto Rico Cancer Drugs Market
4.4.2.10.1. Puerto Rico Sales Of Top 10 Cancer Drugs
4.4.2.11. Morocco Cancer Drugs Market
4.4.2.11.1. Morocco Sales Of Top 10 Cancer Drugs
4.4.2.12. Costa Rica Cancer Drugs Market
4.4.2.12.1. Costa Rica Sales Of Top 10 Cancer Drugs
4.4.2.13. Lebanon Cancer Drugs Market
4.4.2.13.1. Lebanon Sales Of Top 10 Cancer Drugs

Chapter 5: Company Profiles
5.1. Abbvie Inc.
5.1.1. Company Overview
5.1.2. Company Snapshot
5.1.3. Operating Business Segments
5.1.4. Product Portfolio
5.1.5. Business Performance
5.1.6. Key Strategic Moves And Developments
5.2. Astellas Pharma Inc.
5.2.1. Company Overview
5.2.2. Company Snapshot
5.2.3. Operating Business Segments
5.2.4. Product Portfolio
5.2.5. Business Performance
5.3. Astrazeneca Plc
5.3.1. Company Overview
5.3.2. Company Snapshot
5.3.3. Operating Business Segments
5.3.4. Product Portfolio
5.3.5. Business Performance
5.3.6. Key Strategic Moves And Developments
5.4. Bristol-Myers Squibb Company
5.4.1. Company Overview
5.4.2. Company Snapshot
5.4.3. Operating Business Segments
5.4.4. Product Portfolio
5.4.5. Business Performance
5.4.6. Key Strategic Moves And Developments
5.5. Celgene Corporation
5.5.1. Company Overview
5.5.2. Company Snapshot
5.5.3. Operating Business Segments
5.5.4. Product Portfolio
5.5.5. Business Performance
5.6. F. Hoffmann-La Roche Ltd.
5.6.1. Company Overview
5.6.2. Company Snapshot
5.6.3. Operating Business Segments
5.6.4. Product Portfolio
5.6.5. Business Performance
5.6.6. Key Strategic Moves And Developments
5.7. Johnson & Johnson (Janssen Global Services, Llc,)
5.7.1. Company Overview
5.7.2. Company Snapshot
5.7.3. Operating Business Segments
5.7.4. Product Portfolio
5.7.5. Business Performance
5.8. Merck & Co., Inc.
5.8.1. Company Overview
5.8.2. Company Snapshot
5.8.3. Operating Business Segments
5.8.4. Product Portfolio
5.8.5. Business Performance
5.8.6. Key Strategic Moves And Developments
5.9. Novartis Ag
5.9.1. Company Overview
5.9.2. Company Snapshot
5.9.3. Operating Business Segments
5.9.4. Product Portfolio
5.9.5. Business Performance
5.10. Pfizer Inc.
5.10.1. Company Overview
5.10.2. Company Snapshot
5.10.3. Operating Business Segments
5.10.4. Product Portfolio
5.10.5. Business Performance

*Full List of Tables and Figures Available on Enquiry.
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5

FEATURED COMPANIES

  • AbbVie Inc.
  • Astellas Pharma Inc.
  • AstraZeneca PLC
  • Celgene Corporation
  • F. Hoffmann-La Roche Ltd.
  • Merck & Co. Inc.
  • MORE
According to the report titled, 'Top 10 Cancer Drugs Market: Opportunity Analysis and Industry Forecast, 2018-2026', the top 10 cancer drugs market accounted for $63,619 million in 2018, and is expected to reach $129,948 million by 2026, registering a CAGR of 9.8% from 2019 to 2026.

Cancer caused when the cells present in the body grow at an uncontrolled rate leading to the formation of a tumor. Cancer has different stages based on its progression. Metastasis is the final stage of the disease, which is marked by the invasion of tumor into others parts of body. The management of cancer in patients requires the use of different forms of drugs such as hormonal therapy, immunotherapy, targeted therapy, and others.

Drugs such as Revlimid, Opdivo, Keytruda, Herceptin, Avastin, Rituxan, Imbruvica, Neulasta/Peglasta, Ibrance, and Zytiga are the top selling drugs in 2018. The key drivers of the global cancer drugs market are increase in incidence of cancer, rise in adoption of advance therapies such as biological & targeted drug therapies, surge in geriatric population, and rise in collaborations & partnerships to facilitate drug development. In addition, availability of the drugs and increase in healthcare expenditure have significantly contributed toward the growth of this market. Increase in number of pipeline drugs along with high potential of emerging economies are further expected to provide lucrative opportunities for market expansion. However, high cost involved in new drug development and adverse effects related to cancer drugs are expected to impede the market growth.

The global top 10 cancer drugs sales is segmented on the basis of region. Regionally, the market is studied across Europe (Russia, Netherlands, Switzerland, Sweden, Belgium, Austria, Norway, Denmark, Poland, Finland, Portugal, Greece, Ireland, Czech Republic, Hungary, Romania, Ukraine), Asia-Pacific (Taiwan, Indonesia, New Zealand, Singapore, Malaysia, Vietnam, Myanmar, Sri Lanka, Macau, Nepal), and LAMEA (Turkey, Venezuela, Colombia, Argentina, Iran, Israel, Chile, Algeria, United Arab Emirates, Puerto Rico, Morocco, Costa Rica, Lebanon).

Key Findings of the Top 10 Cancer Drugs Market:
Revlimid occupied 15.22% share of the global top 10 cancer drugs sales in 2018.
Keytruda is anticipated to grow at the highest rate during the analysis period.
The Europe cancer drugs accounted for 21.21% share of the global top 50 cancer drugs sales in 2018.
The top 10 cancer drugs accounted for 52.96% share of the global top 50 cancer drugs sales in 2018.
Asia-Pacific is anticipated to grow at the highest rate during the analysis period, followed by LAMEA
In the current scope of the study, Europe was the leading revenue contributor to the market in 2018, owing to high adoption rate of cancer drugs. However, Asia-Pacific is expected to grow at the highest CAGR from 2019 to 2026, owing to increase in adoption of advanced therapies, surge in research, development, & innovation activities; and rise in awareness related to different cancers.
Note: Product cover images may vary from those shown
5 of 5
  • AbbVie Inc.
  • Astellas Pharma Inc.
  • AstraZeneca PLC
  • Bristol-Myers Squibb Company
  • Celgene Corporation
  • F. Hoffmann-La Roche Ltd.
  • Johnson & Johnson (Janssen Global Services LLC)
  • Merck & Co. Inc.
  • Novartis AG
  • Pfizer Inc.
Note: Product cover images may vary from those shown
6 of 5

The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.

They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.

They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:

  • Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
  • Scientific and technical writings for product information and related preemptions
  • Regional government and statistical databases for macro analysis
  • Authentic news articles and other related releases for market evaluation
  • Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast

Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.

Loading
LOADING...

Adroll
adroll